Objective: By modelling patient exposures of interventional procedures, this study compares the reduction of radiation detriment between Digital Variance Angiography (DVA) and Digital Subtraction Angiography (DSA).

Methods: The paper presents a retrospective risk assessment using an in-house developed tool on 107 patient exposures from a clinical trial of DVA used to diagnose peripheral arterial disease (PAD). DICOM exposure parameters were used to initiate the PENELOPE (PENetration and Energy LOss of Positrons and Electrons) Monte Carlo simulation, radiation quality and quantity, and irradiation geometry. The effective dose and the lifetime attributable risk (LAR) for cancer incidence and mortality are calculated based on the International Commission on Radiation Protection's (ICRP) 103 recommendations and the Committee on the Biological Effects of Ionising Radiations' latest (BEIR VII) report, respectively.

Results: The study found that procedures conducted using DVA significantly reduce the radiation exposure of patients, compared to DSA. The collective effective dose for the DVA group was 58% lower than that for the DSA group. Correspondingly, the LAR of different organs showed a substantial decrease for cancer incidence (25-75%) and mortality (51-84%).

Conclusion: DVA demonstrates a considerable reduction in physical dosimetric quantities and consequently effective dose and cancer risk, suggesting its potential as a safer alternative to DSA in interventional radiology. The use of DVA supports the optimisation of patient radiation protection and aligns with the principles of ALARA (as low as reasonably achievable).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2024.104859DOI Listing

Publication Analysis

Top Keywords

effective dose
12
digital variance
8
subtraction angiography
8
monte carlo
8
patient exposures
8
cancer incidence
8
dva
6
radiation
5
comparative effectiveness
4
effectiveness digital
4

Similar Publications

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.

Acta Dermatovenerol Croat

November 2024

Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;

We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).

View Article and Find Full Text PDF

Radiation therapy is one of the most effective treatments for approximately 60% of patients with cancer. During radiation exposure, the overproduction of reactive oxygen species (ROS) disrupts the lipid layer of the membrane, leading to subsequent peroxide radical formation. Cimetidine (Cim) and famotidine (Fam) are histamine H2 receptor antagonists (H2 blocker), also known as peptic ulcer drugs, that exert radioprotective effects.

View Article and Find Full Text PDF

Background: There is consensus on the safety of standard dose direct oral anticoagulants (DOACs) for stroke prevention in patients undergoing cardioversion of atrial fibrillation (AF), but outcomes of reduced dose DOACs in this setting remain unclear.

Objective: This systematic review and meta-analysis aimed to compare the rate of cardioversion-associated thromboembolic events between patients taking reduced dose DOACs and those receiving standard dose anticoagulation.

Methods: A systematic search was conducted for studies published between January 1, 2009, and February 16, 2024 in PubMed, Embase, and Cochrane Central Register of Controlled Trials.

View Article and Find Full Text PDF

Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.

Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.

Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!